SCHEDULE: Deerfield Management Reduces Stake in ARS Pharmaceuticals to 9.90%
Schedule 13D Amendment
Deerfield Management Company and its affiliated funds have reduced their beneficial ownership in ARS Pharmaceuticals, Inc. to 9.90% of common stock through recent open market sales.
Summary
- Deerfield Management Company, L.P. and its affiliates, including Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., and James E. Flynn, filed an Amendment No. 3 to their Schedule 13D regarding ARS Pharmaceuticals, Inc. common stock.
- The reporting persons collectively beneficially own 9,724,508 shares of ARS Pharmaceuticals, Inc. common stock, representing 9.90% of the outstanding shares.
- This percentage is based on 98,213,561 shares of common stock outstanding as of May 12, 2025, as reported by ARS Pharmaceuticals, Inc. in its Form 10-Q.
- On June 27, 2025, Deerfield Private Design Fund III, L.P. sold 395,075 shares at a weighted average price of $18.45 per share, with a price range of $18.20 to $18.89.
- On the same date, Deerfield Private Design Fund IV, L.P. sold 395,074 shares at a weighted average price of $18.45 per share, with a price range of $18.20 to $18.89.
- All transactions were effected in open market transactions on the Nasdaq Global Market.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake, which can be interpreted as a decrease in confidence or a strategic divestment, despite the transactions being described as 'ordinary course of business'.
Negatives
- A significant institutional investor, Deerfield Management, reduced its stake in ARS Pharmaceuticals, Inc. by selling a total of 790,149 shares.
- The sales occurred at a weighted average price of $18.45 per share, potentially indicating a lack of conviction at higher price levels or a portfolio rebalancing.
Future Outlook
NA
Industry Context
This Schedule 13D amendment reflects a change in institutional ownership within the biotechnology/pharmaceutical sector. While it indicates a reduction in stake by a prominent healthcare-focused investment firm, it does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders may perceive the reduction in stake by a major institutional investor as a negative signal, potentially impacting investor confidence and the company's stock price.
- The transaction itself does not directly impact employees, customers, suppliers, or creditors of ARS Pharmaceuticals, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-05-12 | Date of ARS Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q, reporting 98,213,561 shares of Common Stock outstanding. |
| 2025-06-27 | Date of open market sales of ARS Pharmaceuticals, Inc. common stock by Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. |
| 2025-07-02 | Date of event requiring the filing of this Schedule 13D Amendment No. 3. |
Recommendation
holdKeywords
ARS Pharmaceuticals Inc., Deerfield Management Company, Schedule 13D, Common Stock, Beneficial Ownership, Institutional Investor, Stock Sale, Nasdaq Global Market, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.